JUNE 2000
|
|
|
- へいぞう いりぐら
- 5 years ago
- Views:
Transcription
1 VOL.48 NO.6
2 JUNE 2000
3 VOL.48 NO.6 Fig. 1. Chemical structure of pazufloxacin and pazufloxacin mesilate.
4 JUNE 2000
5 VOL.48 NO.6
6 JUNE 2000 Table 1. Items and schedule of laboratory tests
7 VOL.48 NO.6
8 Table 2. Criteria for evaluation of usefulness Table 3. Grading of symptoms, signs, and laboratory findings M: mucous, PM: mucopurulent, P: purulent
9 VOL.48 NO.6
10 JUNE 2000 Table 4. Case distribution investigational drug was administered to a total of 233 patients in this study, but 1 case was excluded from the evaluation because of its inappropriateness for GCP.
11 VOL.48 NO.6 Table 5. Reason for incomplete cases
12 444 JUNE ZU00 Table 6. Background of the patients Fis: Fisher's exact probability method
13 VOL.48 NO.6 Table 7. Background of the patients: Initial symptoms, signs, and laboratory findings Fis: Fisher's exact probability method (Property of sputum) PM: mucopurulent, P: purulent
14 JUNE 2000 Table 8. Background of the patients: causative organisms Fis: Fisher's exact probability method Table 9. Susceptibility distribution of causative organisms to pazufloxacin and ceftazidime Table 10. Clinical efficacy Fis: Fisher's exact probability method, Efficacy rate: (excellent+ good)/ No.of patients
15 VOL.48 NO.6 Table 11. Clinical efficacy according to the background factors of the patients Fis: Fisher's exact probability method, Efficacy rate:(excellent+ good)/ No.of patients
16 JUNE 2000 Table 12. Clinical efficacy in non- responders to prior treatment with other antimicrobial agents Fis: Fisher's exact probability method, Efficacy rate:(excellent+good)/ No. of patients
17 VOL.48 NO.6 Table 13. Clinical efficacy in bacteriologically documented cases Fis: Fisher's exact probability method, Efficacy rate:(excellent+good)/ No. of patients
18 Table 14. Clinical efficacy in bacteriologically documented cases (indications for CAZ) Fis: Fisher's exact probability method, Efficacy rate: (excellent + good) /No. of patients pneumoniae, Acinetobacter calcoaceticus
19 VOL.48 NO.6 Table 15. Bacteriological response classified according to causative organism Fis: Fisher's exact probability method, Elimination rate: eliminated/ No, of patients
20 JUNE 2000 Table 16. Bacteriological response classified according to causative organism (indications for CAZ) Fis: Fisher's exact probability method, Elimination rate: eliminated/ No. of patients
21 VOL.48 NO.6 Table 17. Elimination rate of causative organisms Fis: Fisher's exact probability method, Elimination rate: eliminated/ No. of strains
22 Table 18. Elimination rate of causative organisms (indications for CAZ) Fis: Fisher's exact probability method, Elimination rate: eliminated/no, of strains Table 19. Organisms appearing after treatment Incidence: No. of patients in whom organisms appeared/no. of patients
23 VOL.48 NO.6 Table 20. Changes in symptoms, signs, and laboratory findings Improvement rate: Improved/ No, of patients
24 JUNE 2000 Table 21. Changes in chest X-ray findings Improvement rate: Improved/ No, of patients Table 22. Adverse effects Fis: Fisher's exact probability method
25 VOL.48 NO.6 Table 23. Abnormal laboratory findings Fis: Fisher's exact probability method Table 24. Overall safety Safety rate: safe/ No. of patients Table 25. Usefulness Usefulness rate: (very useful+ useful)/ No. of patients
26 JUNE 2000 Table 26. Clinical efficacy (all patients with bacterial pneumonia) Efficacy rate: (excellent+ good )/ No. of patients PZFX: pazufloxacin mesilate. CAZ: ceftazidime Table 27. Results of logistic regression models PZFX: pazufloxacin, CAZ: ceftazidime
27 VOL.48 NO.6 Table 28. Estimated efficacy rates and their 90% confidence intervals under the adequate logistic regression model
28 JUNE 2000
29 VOL.48 NO.6 17) Haddow A, Greene S, Heinz G, et al.: Ciprofloxacin (intravenous/ oral) versus ceftazidime in lower respiratory tract infections. Am J Med, 87 (Suppl 5 A): 112 S-115 S Clinical evaluation of pazufloxacin mesilate for bacterial pneumonia Phase III comparative study of pazufloxacin mesilate versus ceftazidime \ Kaoru Shimada1) a) b), Shosaku Abe 2), Takuya Fujishima 2), Akihiko Honma 2), Kunio Shirato 3), Isao Ohno 3), Makoto Takahashi 3), Munehiko Ishii 3), Shinsaku Maeda 3), Masahiro Sakamote, Kazuki Konishi 3), Toshihiro Nukiwa 4), Akira Watanabe 4), Kousaku Nagai 4), Hiroaki Takeda 5), Takeshi Osonoi6), Hiroyuki Kobayashi 7), Shin Kawai 7), Tatsuo Hosoyas 8), Kohya Shiba 8), Kazuhisa Okada 8), Koichiro Kudo 9), Nobuyuki Kobayashi 9), Yasuyuki Sane 10), Yoshitaka Nakamori 11), Masaru Koyama 12), Tadashi Horiuchi 13), Harumi Shishido 14), Satoshi Mitarai 14), Shoichiro Irimajiri 15), Yasuo Matsuoka 15), Norihiko Koidon 15), Iwao Sakurai 16), Fumio Matsumoto 16), Shigeki Odagiri 17), Kaneo Suzuki 17), Yuji Watanuki 17), Masaaki Arakawals 18), Kenichi Igarashi 18), Osamu Sekine 19), Yasutoshi Suzuki19), Nobuki Aoki 20), Koichi Wada 21), Saburo Izumi 22), Atsuhiko Sato 23), Kingo Chida 23), Keishi Hayakawa 23), Takeshi Yagi 23), Masatoshi Iwata 23)Atsushi Yoshitomi 23), Katsunori Tukamoto 23), Yasunobu Noda 24), Kenzo Takagi 25), Hiroyuki Taniguchi 25), Takuya Kurosawa 26), Fumio Miki 27), Yuji Tohda 28), Bun ichi Umeda 29), Takashi Nishimura 29), Nobuhiro Narita 30), Keiichi Mikasa 30), Mitsuru Konishi 30), Toshiharu Matsushima 31), Yoshihito Niki.31), Nirou Okimoto 32), Takayuki Karino 32), Rinzo Soejima 33), Mitsuru Muguruma 34), Shin Kawahara 35), Atsuhiko Tada 35), Michio Yamakide 36), Soichiro Hozawa 36), Takao Sasaki 37), Kenji Kono 38), Kotaro Oizumi 39), Masaharu Kinoshita 39). Masao Kawahare 39), Shigeru Kohno 40), Masami Watanabe 40), Rokushi Oka 40), Hiroyuki Hori 40), Yuichi Inoue 40), Satoru Fujino 40), Yoshihiro Yamamoto 40), Tohru Ishino 40), Hideaki Ohno 40), Kazuhiro Okune 40), Kiyoyasu Fukushime 40), Tsuyoshi Nagataken 41), Misao Tao 41), Masayuki Ando 42), Moritaka Sugau 42), Sato Keizo 42), Kiyotaka Ito 42), Toshinori Doi 42), Tetsunobu Sakata 42), Masami Tamanoi 42), Katsumasa Tokunaga 42), Kazuyasu Shimazu 42), Hajime Iwagoe 42), Masaru Nasu 42), Hiroshi Kawano 43), Atsushi Saito 44), Masao Tateyamau 44),
30 JUNE 2000 Atsushi Ohhama Toru Kubota 44) and Mitsuyoshi Nakashima Department of Internal Medicine, Tokyo Senbai Hospital, Mita, Minato ku, Tokyo , Japan The Third Department of Internal Medicine, Sapporo Medical University, School of Medicine, and Affiliated Hospital 3) Th e First Department of Internal Medicine, Tohoku University, School of Medicine, and Affiliated Hospitals ) Department of Respiratory Medicine, Institute of Development, Aging and Cancer, Tohoku Hospital Department of Internal Medicine, Saiseikai Yamagata Saisei Hospital University, and Affiliated ) Department of Internal Medicine, Mito Cooperative Hospital The First Department of Internal Medicine, Kyorin University, School of Medicine The Second Department of Internal Medicine, The Jikei University School ) Division of Respiratory Diseases, International Medical Center of Japan ) Department of Allergy and Respiratory Diseases, Doai Memorial Hospital Department of Respiratory Diseases, Mishuku Hospital Department of Internal Medicine, Tokyo kyosai Hospital 13 ) Department of Pharmacology and Allergy, Kanto Central Hospital ) Department of Respiratory Diseases, Tokyo National Chest Hospital Department of Internal Medicine, Kawasaki Municipal Hospital of Medicine, and Affiliated Hospital ) Department of Internal Medicine, Kanagawa Prefecture Midwives and Nurses Training School Hospital ) Department of Respiratory Diseases, Kanagawa Prefectural Cardiovascular and Respiratory Disease Center Second Department of Internal Medicine, Niigata University School of Medicine ) Department of Internal Medicine, Suibarago Hospital ) Department of Internal Medicine, Shinrakuen Hospital ) Department of Respiratory Diseases, National Sanatorium Nishi Niigata Chuou Hospital ) Department of Internal Medicine, Toyama Prefectural Central Hospital The Second Department of Internal Medicine, Hamamatsu University School of Medicine, and Affiliated Hospitals ) Department of Respiratory Diseases, Toyohashi Municipal Hospital The Second Department of Internal Medicine, Nagoya University, School of Medicine, and Affiliated Hospital Department of Respiratory Medicine, National Minami Kyoto Hospital Department of Internal Medicine, Tane General Hospital ) The Fourth Department of Internal Medicine, Kinki University, School of Medicine Division of Respiratory Diseases, Kobe City General Hospital ) The Second Department of Internal Medicine, Nara Medical University Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School Department of Internal Medicine, Kawasaki Medical School Kawasaki Hospital ) Kawasaki University of Medical Welfare ) Department of Internal Medicine, Okayama Saiseikai General Hospital ) Department of Internal Medicine, National Sanatorium Minami Okayama Hospital ) Second Department of Internal Medicine, Hiroshima University, School of Medicine, and Affiliated Hospital ) The Third Department of Internal Medicine, Tottori University, School of Medicine ) Second Department of Internal Medicine, Fukuoka University, School of Medicine ) The First Department of Internal Medicine, Kurume University, School of Medicine, and Affiliated Hospital ) The Second Department of Internal Medicine, Nagasaki University, School of Medicine, and Affiliated Hospitals ) Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki university, and Affiliated Hospital The First Department of Internal Medicine, Kumamoto University, School of Medicine, and Affiliated Hospitals ) The Second Department of Internal Medicine, Oita Medical University, and Affiliated Hospital ) The First Department of Internal Medicine, School of Medicine, University of the Ryukyus, and Affiliated Hospitals ) Department of Pharmacology, Hamamatsu University School of Medicine
31 VOL.48 NO.6 The clinical efficacy, safety, and usefulness of pazufloxacin mesilate, a new quinolone for injection, were evaluated in bacterial pneumonia or lung abscess in a comparative study versus ceftazidime (CAZ). As a rule patients received either 500 mg (as pazufloxacin) of pazufloxacin mesilate b. i. d. or 1,000 mg (potency) of CAZ b. i. d., intravenously, for 14 days (28 vials). The following results were obtained in this trial. 1. A total of 232 patients were evaluated in this study, and 185 of them (bacterial pneumonia: 173 cases; lung abscess: 12 cases) were evaluated for clinical efficacy. The cases evaluated for adverse effects, abnormal laboratory findings, overall safety, and usefulness amounted to 225, 208, 210, and 182, respectively. 2. The clinical efficacy rate was 90.7%(78/ 86) in the pazufloxacin mesilate group and 89.9%(89/ 99) in the CAZ group. Both groups showed high efficacy. Since the 90% confidence interval of the efficacy rate difference between the two groups was- 7.5 `9.1%, the clinical equivalency (non- inferiority) of the pazufloxacin mesilate group to the CAZ group was demonstrated at = 10%. Although significant bias was found between the two groups in the patient background factors concerning "sex","concomitant drugs", "body temperature","esr","crp", and "chest X- ray findings", clinical equivalency of the pazufloxacin mesilate group to the CAZ group was conclued after correction for these biases too. 3. Among the cases evaluated for clinical efficacy, 85 cases in which the causative organisms were isolated were evaluated for bacteriological effects. The bacteriological eradication rate was 81.1%(30/ 37) in the pazufloxacin mesilate group and 100%(48/ 48) in the CAZ group, and the difference between the two groups was statistically significant (p= 0.002, Fisher's exact probability method). 4. The incidence of adverse effects was 5.5%(6/ 110) in the pazufloxacin mesilate group and 7.8%(9/ 115) in the CAZ group, and the difference between the groups was not significant. The incidence of abnormal laboratory findings was 31.0%(31/ 100) in the pazufloxacin mesilate group and 29.6% (32/ 108) in the CAZ group, and the difference between the groups was not significant. None of the adverse effects were serious. 5. The safety rate was 65.3%(66/ 101) in the pazufloxacin mesilate group and 62.4%(68/ 109) in the CAZ group, and the difference between the groups was not significant. 6. The usefulness rate was 86.6%(71/ 82) in the pazufloxacin mesilate group and 82.0%(82/ 100) in the CAZ group, and the difference between the groups was not significant. These findings indicate that pazufloxacin mesilate is one of the most effective drugs for bacterial pneumonia
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
Key words: bacterial pneumonia, cefepime, ceftazidime, comparative study
Key words: bacterial pneumonia, cefepime, ceftazidime, comparative study Staphylococcus aureus, Streptococcus influenzae, S. pneumoniae, Klebsiella Fig. 1 Chemical structure of cefepime Table 1 Clinical
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
Takeji NISHIKAWA, M. D.*, Takashi HARADA, M. D.** and Tatsuya IZUML M. D. Toshiyuki SUGI, M. D. Hiroshi HANYAKU, M. D. Shun-ichi MIYAKAWA, M. D. and Masaru TANAKA, M. D. Nobuko INAMOTO, M. D. and Hironori
CHEMOTHERAPY MAY 1992
CHEMOTHERAPY MAY 1992 Fig. 1. Package of test drugs. CHEMOTHERAPY MAY 1992 VOL.40 S-3 Table 1. Items and schedule of laboratory tests CHEMOTHERAPY MAY 1992 Table 2. Evaluation criteria of symptoms, signs
CHEMOTHERAPY Silver sulfadiazine (T 107) CHEMOTHERAPY Fig. 1 Item of patients Table 1 Criteria of bacteriological efficacy by the Committee xcellent: E Score of infection becomes to 0% at the end of medication.
Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
Fig. 1 Chemical structure of norfioxacin (AM-715)
Fig. 1 Chemical structure of norfioxacin (AM-715) Table 1 Serum and biliary concentration of norfloxacin (AM-715) Table 2 Protocol for clinical evaluation of norfloxacin (AM-715) in the treatment of biliary
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,
Table 1. Influence of urine ph on MBCs of new quinolones against Escherichia coli NIHJ JC-2 and Pseudomonas aeruginosa 18S; MBCs in urine were compared with those in Miieller-Hinton broth. Table 2. Influence
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s
Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s Vesical irritability without urinary Pain. Pyuria 10/
CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
Staphylococcus aureus (MSSA), Streptococcus pneumoniae, Enterococcus faecalis Pseudomonas aeru- ginosa, Enterobacter cloacae, Citrobacter freun- Fig.
Key words : cefluprenam, seven days therapy, respiratory tract infection Staphylococcus aureus (MSSA), Streptococcus pneumoniae, Enterococcus faecalis Pseudomonas aeru- ginosa, Enterobacter cloacae, Citrobacter
Fig. 1 Chemical structure of KW-1070
Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
CHEMOTHERAPY MAY. 1988
CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY Fig. 1 Chemical structure CHEMOTHERAPY MAY. 1988 VOL.36 5-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY
VOL. 45 NO. 6 Fig. 1. Chemical structure of grepafloxacin.
JUNE 1997 VOL. 45 NO. 6 Fig. 1. Chemical structure of grepafloxacin. JUNE 1997 GPFX: grepafloxacin, OFLX: ofloxacin Fig. 2. Package of test drugs. VOL. 45 NO. 6 Table 1, Clinical study items and schedule
CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
Fig. 1 Chemical structure of Flurbiprofen Molecular formula : C1S H13 F02 Molecular weight : Chemical name : 2-( 2 -fluoro - 4 -biphenyly1 ) pr
Key words : Flurbiprofen, Acute Upper Respiratory Tract Inflammation, Double-Blind Clinical Evaluation Fig. 1 Chemical structure of Flurbiprofen Molecular formula : C1S H13 F02 Molecular weight : 244.27
Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo
Kekkaku Vol. 79, No. 1: 17-24, 2004 17 (Received 21 Aug. 2003/Accepted 18 Nov. 2003) Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly
Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic
COMPARATIVE CLINICAL EFFECT OF AMIKACIN AND GENTAMICIN ON COMPLICATED URINARY TRACT INFECTIONS BY DOUBLE-BLIND METHOD Tsuneo Nishiura and Yukimichi Kawada Department of Urology, Gifu University School
Table 1.Distribution and number of cases with acute upper respiratory tract infections classified according to antimicrobial agents administered Table 2. Distribution of cases which were enrolled to set
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia
Fig. 1 Chemical structure of norfloxacin Table 1. Institutes attended to the study The Department of Dermatology, Defense Medical College The Department of Dermatology, School of Medicine, Teikyo University
1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):
VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover
VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients
CHEMOTHERAPY FEB Table 1 Background of volunteers
CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
VOL.39 S-3
VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose
Key words: pazufloxacin, infectious enteritis, antibacterial activity, fecal concentration, fecal microflora : Table 1-1 Criteria for bacteriological efficacy of pazufloxacin on Shigella spp. and V. cholerae
Key words: HAPA-B, AMK, Comparative study, Respiratory tract infections
Key words: HAPA-B, AMK, Comparative study, Respiratory tract infections Fig. 1 Chemical structure of HAPA-B Table 1 Collaborating clinics The First Department of Internal Medicine, Kyorin University, School
400 CHEMOTHERAPY JAN Table 1 Cases of drop outs
VOL. 23 NO. 1 CHEMOTHERAPY 399 Fig. 1 Stracture of cephradine Chemical name : 7-CD(-)-2-amino-2-(1,4-cyclohexadien-1-y1) -acetamido) -3-methyl-8-oxo-5-thia-1-aza- -bicyclo [4. 2. 0] oct-2-ene-2-carboxylic
Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331
Key words: Norfloxacin (NFLX), Infectious enteritis, Double-blind method
Key words: Norfloxacin (NFLX), Infectious enteritis, Double-blind method Fig. 1 Chemical structure Norfloxacin (NFLX) Pipemidic acid (PPA) Fig. 2 Package of test drugs Table 1 Criteria for evaluation
VOL. 34 S-2 CHEMOTH8RAPY 913
VOL. 34 S-2 CHEMOTH8RAPY 913 914 CHEMOTHERAPY APR. 1986 Fig. 1 Chemical structure of T-2588 and T-2525 T- 2588 pivaloyloxymethyl (+ )- (6 R, 7 R)-7-[(Z)-2- (2-amino- 4-thiazolyl)-2-methox yiminoacetamido]-3-[(
VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination Fig. 1 The value of fungal index and D- arabinitol/creatinine. Fungal index was mesured by Endotoxin D and Endospecy
366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
Fig. 1 Chemical structure Lomefloxacin(LFLX,NY-198) Pipemidic acid(ppa)
Key words : Lomefloxacin (LFLX, NY-198), Infectious enteritis, Double blind method Fig. 1 Chemical structure Lomefloxacin(LFLX,NY-198) Pipemidic acid(ppa) Fig. 2 Package of test drugs LFLX group PPA group
Table1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
04-c-„FŒ{›xŒ¾-4.01
544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli
Osamu NEMOTO, M.D. Clinical and Bacteriological Research of Sucrose/ Povidone-Iodine Ointment (U-PASTA kowa) for Pressure Sores and Skin Ulcers Osamu Nemoto Department of Dermatology,Tonan Hosptal
Key words: RU 28965, roxithromycin, midecamycin acetate Pneumonia, double-blind method
Key words: RU 28965, roxithromycin, midecamycin acetate Pneumonia, double-blind method Fig. 1 Chemical structure of RU Table 1 Evaluation criteria for signs, symptoms and laboratory findings 1) M: mucous
Key words: atypical pulmonary mycobacteriosis, Mycobacterium avium complex, bronchial washing, transbronchial lung biopsy Table 1 Background data of 14 patients Old pul. tbc: sclerosing pulmonary tuberculosis
VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
Title 神経因性膀胱にともなう排尿障害に対する塩酸ブナゾシンの臨床効果 - 二重盲検比較試験による検討 - 小柳, 知彦 ; 富樫, 正樹 ; 丸, 彰夫 ; 折笠, 精一 ; 相馬, Author(s) 崎, 淳 ; 安田, 耕作 ; 阿曽, 佳郎 ; 本問, 之夫 ; 三宅, 弘厚生 ; 熊
Title 神経因性膀胱にともなう排尿障害に対する塩酸ブナゾシンの臨床効果 - 二重盲検比較試験による検討 - 小柳, 知彦 ; 富樫, 正樹 ; 丸, 彰夫 ; 折笠, 精一 ; 相馬, Author(s) 崎, 淳 ; 安田, 耕作 ; 阿曽, 佳郎 ; 本問, 之夫 ; 三宅, 弘厚生 ; 熊澤, 淨一 ; 武井, 実根雄 Citation 泌尿器科紀要 (1990), 36(10): 1233-1252
CHEMOTHERAPY
CHEMOTHERAPY VOL.40 S-3 CHEMOTHERAPY Table 1. No.of patients studied CHEMOTHERAPY Table 2. Age of patients Minimum age: 16 years old Maximum age: 93 years old Table 3. Severity of illness of patients Table
VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
Special IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, School of Medicine, Tokushima University, Tokushima Fetal
8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
208 ( 2 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 Cefditoren pivoxil (CDTR-PI) MS MS 10%
207 ( 1 ) Cefditoren pivoxil G 2010 2 2 2006 3 Cefditoren pivoxil CDTR-PI MS 10% CDTR-PI 305 2,144 2,006 1,958 1.79% 36 2,006 26 (1.30%) CDTR-PI CDTR-PI (9 mg/kg/day) 1.5 2 (2.70%) 2 (1.92%) 93.5% 1,831
Table 1 Method of administration Inactive placebo. Table 2 Critoria for overall ef4fficy rating by committee L Severity and scores of main symptoms 1) Acute tonsillitis (Peritonsillids, Peritonsillar abscess)
VOL. 21 NO. 2 CHEMOTHERAPY 395
394 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 395 396 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 397 398 CHEMOTHERAPY MAR. 1973 VOL. 2 1 NO. 2 CHEMOTHERAPY 399 400 CHEMOTHERAPY MAR. 1973
CHEMOTHERAPY JAN Fig. 1 Structure of cephradine
VOL. 23 NO. 1 CHEMOTHERAPY 409 CHEMOTHERAPY JAN. 1975 Fig. 1 Structure of cephradine VOL. 23 NO. 1 CHEMOTHERAPY 411 Table 1 Reason for drop-out 412 CHEMOTHERAPY JAN. 1975 VOl. 23 NO. 1 CHEMOTHERAPY 413
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
19 OUR EXPERIENCE IN COMBINED BALNEO AND CHRYSOTHERAPY FOR RHEUMATOID ARTHRITIS by Hidemitsu EZAWA (Director: Prof. Hiroshi MORI NAG A), Department ofinternal Medicine, Institute for Thermal Spring Research,
udc-3.dvi
49 UDC 371.279.1 3 4 753 1 2 2 1 2 47 6 2005 11 14 50 No.35, 2006 1 1.1 AO 2003 2004 2005 2005 1 1 2005 1998 1999 2002 12 11 2000 SAT ACT Law School Admission Test LSAT Medical College Admission Test MCAT
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2305(45) 2306(46) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2307(47) 2308(48) THE JAPANESE
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K
OCT. 1986 Fig. 1 Chemical structure of CVA-K VOL.34 S-4 heart infusion broth (Difco) 37.0 g, Resazurin 0.1% alcoholic solution (Wako) 1.0 ml, L-Cystein-HCl H2O (Wako) 0.5 g, Bact agar (Difco) 1.0 g, Deionized
Table 1 Profiles of 28 patients with Legionella pneumonia in Japan, 1980-1990 a) Y Taguchi, personal communication b) M. Hayase, personal communicatio
Key words: Legionella pneumonia, culture-positive, Japanese patients Legionella (L. pneumophila (L. micdadei, L. bozemanii, Table 1 Profiles of 28 patients with Legionella pneumonia in Japan, 1980-1990
Table 1 Classification of female patients with vealcal irritating symptom by their signs Urination pain with other vesical irritability or not Table 2 Serum levels of DL-8280 after a single oral administration
56 pp , 2005 * ******* *** ** CA CAMA
Title 成人知的障害者の加齢に伴う外観的変化に関する研究 : 知的障害者用外観的老化微候測定法を用いた検討 Author(s) 春日井, 宏彰 ; 菅野, 敦 ; 橋本, 創一 ; 桜井, 和典 ; 片瀬, Citation 東京学芸大学紀要. 第 1 部門, 教育科学, 56: 415-425 Issue Date 2005-03-00 URL http://hdl.handle.net/2309/2097
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin 1380 CHEMOTHERAPY MAR. 1975 Table 2 Susceptibility of isolated Pseudomonas aeruginosa to various antibiotics
semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG
CLINICAL STUDIES OF UROGENITAL INFECTIONS WITH CHLAMYDIA TRACHOMA TIS Report 2. The Epidemiology of Chlamydial Infections in Okayama District in Japan and Detection of Antibodies to Chlamydiae in the Sera
Fig. 1. Chest X-ray film on admission showed a mass in the left middle lung field and multiple nodular densities in the bilateral lung fields. Fig. 3.
A Case of Slow-growing Mucous-producing Adenocarcioma of the Lung Key words: Mucous-producing lung adenocarcinoma, Slow-growing, Bronchial gland cell type adenocarcinoma, Adenoid cystic carcinoma Table
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
indd
12 61 1 2011 原著 1)2)5) 1) 1)2) 1)2)5) 1)3)5) 1)2) 1)2)5) 1)2) 1)2) 2) 2) 4) 1) 1) 2) 3) 4) 5) 2010 10 6 2010 12 6 A Comparative Study of the Effect and Discomfort Produced by Pharyngeal Anesthesia with
名称未設定-1
Study on Clinical Factors Affecting the Fungal Culture Test - Relevance of Dry Mouth - Yoshiko YAMAMURA, Yukihiro MOMOTA, Hideyuki TAKANO, Koichi KANI, Katsumi MOTEGI, Fumihiro MATSUMOTO, Masayuki AZUMA
Title 外傷性脊髄損傷患者の泌尿器科学的研究第 3 報 : 上部尿路のレ線学的研究並びに腎機能について Author(s) 伊藤, 順勉 Citation 泌尿器科紀要 (1965), 11(4): Issue Date URL
Title 外傷性脊髄損傷患者の泌尿器科学的研究第 3 報 : 上部尿路のレ線学的研究並びに腎機能について Author(s) 伊藤, 順勉 Citation 泌尿器科紀要 (1965), 11(4): 278-291 Issue Date 1965-04 URL http://hdl.handle.net/2433/112732 Right Type Departmental Bulletin Paper
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
A comparison of abdominal versus vaginal hysterectomy for leiomyoma and adenomyosis Kenji ARAHORI, Hisasi KATAYAMA, Suminori NIOKA Department of Obstetrics and Gnecology, National Maizuru Hospital,Kyoto,
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
2) Goetz, A., Tsuneishi, N.: Application of molecular filter membranes to the bacteriological analysis of water, J. Am. Water Works Assn., 43 (12): 943-969,1951. 3) Clark, H.F. et al.: The membrane filter
CHEMOT HERAPY
CHEMOT HERAPY CHEMOT HERAPY NOV. 1973 Table 1 Co-laboratory clinics CHEMOT HIRAPY 1537 CHEMOT HERAPY NOV. 1973 CHEMOT HERAPY 1539 Table 3 Distribution by age groups No significant difference in age and
5 3 5 7 5 3 5 2 3 7 5 2 3 7 7 2 2 2 2 3 5 7 5 7 CONTENTS 2 3 5 7 2 2 3 5 2 22 2 2 27 2 2 3 3 32
27 KE I O UNIVERSITY L AW SCHOOL 5 3 5 7 5 3 5 2 3 7 5 2 3 7 7 2 2 2 2 3 5 7 5 7 CONTENTS 2 3 5 7 2 2 3 5 2 22 2 2 27 2 2 3 3 32 2 3 2 3 2 3 5 7 Weekly Schedule Monday Tuesday 2 3 5 Wednesday Thursday
1) Chemical name: Fig. 1 Chemical structure of TE-031 (-)-(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2, PYranosyl)oxy]-14-ethyl-12,13-dihydroxy-7-meth 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexo- oxy-3,5,7,9,11,13-hexamethy1-6-[[3,4,6-trideoxy-3-
<95DB8C9288E397C389C88A E696E6462>
2011 Vol.60 No.4 p.332 338 Usefulness of regional education program for dietary salt reduction: Self-monitoring of urinary salt excretion Kenichiro YASUTAKE[1] Kayoko SAWANO[1] Shoko YAMAGUCHI[1] Hiroko